Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study
The use of RAM prior to nivolumab monotherapy may contribute to prolonged survival in patients with gastric cancer, especially those without peritoneal metastasis.
Authors
- Yuka Obayashi
- Yoshiro Kawahara (ORCID: https://orcid.org/0000-0002-0509-251X)
- Masaya Iwamuro (ORCID: https://orcid.org/0000-0002-1757-5754)
- Koji Miyahara (ORCID: https://orcid.org/0000-0002-3093-4694)
- Yoshiyasu Kono (ORCID: https://orcid.org/0000-0002-4717-5196)
- Shoichiro Hirata
- Kenta Hamada (ORCID: https://orcid.org/0000-0003-0768-3783)
- Masahiko Abe (ORCID: https://orcid.org/0000-0001-6255-316X)
- Masahiro Nakagawa (ORCID: https://orcid.org/0000-0002-6420-2555)
- Motoyuki Otsuka (ORCID: https://orcid.org/0000-0003-2869-2881)
- Yasuhiro Choda
- Seiji Kawano (ORCID: https://orcid.org/0000-0002-7807-5147)
- Michihiro Ishida
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
- Hiroshima City Asa Citizens Hospital (JP)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1007/s40801-024-00460-z
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00